Nanomedicines and Targeted Delivery
Researchers in the School of Biological Sciences and across Cambridge are driving innovation in nanomedicine, drug delivery, and precision medicine. Our work is comprehensive, spanning RNA and protein therapies to smart nanoparticles designed with Click chemistry that can enable highly targeted drug delivery inside the body. Combining these therapeutic advances with deep biological understanding, and with close links with clinical and industry colleagues, Cambridge is uniquely positioned at the forefront of discovery science and transformative healthcare.
Cambridge Nanomedicine Ecosystem
Our scientific excellence in cellular, molecular and tissue biology, nanotechnology innovation and clinical application is driving new opportunities for translation and clinical impact in some of the most pressing disease areas, including cancer, neurodegenerative diseases and cardiovascular disorders. Working closely with lived experience partners, industry collaborations and policy makers, the Cambridge nanomedicine ecosystem is poised to transform the future of medicine.

Recent Highlights
New vaccine effective against coronaviruses that haven’t even emerged yet
Researchers have developed a new vaccine technology that has been shown in mice to provide protection against a broad range of coronaviruses with potential for future disease outbreaks.
Ioanna Mela, the DNA-folding superbug-killer
Ioanna Mela, a researcher working on tiny devices made from intricately folded DNA strands, can make antibiotics work better and even slow the rise of superbugs.
Cambridge spin-out receives £2.2 million to help improve cancer treatments
Vector Bioscience has received a £2.2 million investment to help it take forward its drug delivery platform designed to make RNA cancer therapies more effective.
Nanotechnology Entrepreneurship
Our scientists are extending their impact beyond discoveries in the lab. Their deep understanding of complex problems and innovative solutions forms the basis for new products and services, translating groundbreaking research into real-world impact.
Academic Leads
Marc de la Roche
Biochemistry
David Fairen-Jimenez
Chemical Engineering and Biotechnology
Ljiljana Fruk
Chemical Engineering and Biotechnology
Laura Itzhaki
Pharmacology
Ioanna Mela
Pharmacology
Contributing Researchers
Maria Alcolea, Cambridge Stem Cell Institute
Somenath Bakshi, Engineering
Gill Barnett, Oncology
Claudia Bonfio, Biochemistry
Graham Christie, Chemical Engineering and Biotechnology
Colin Crump, Pathology
Janet Deane, Cambridge Institute for Medical Research
Marc de la Roche, Biochemistry
Lorenzo di Michele, Chemical Engineering and Biotechnology
James Edgar, Pathology
David Fairen-Jimenez, Chemical Engineering and Biotechnology
Angeleen Fleming, Physiology, Development and Neuroscience
Ljiljana Fruk, Chemical Engineering and Biotechnology
Jenny Gallop, Gurdon Institute
Matthew Harper, Pharmacology
Mark Howarth, Pharmacology
Will Ince, Oncology
Laura Itzhaki, Pharmacology
Tony Jackson, Biochemistry
James Jones, Oncology
Bernard Kelly, Cambridge Institute for Medical Research
Patrycja Kozik, MRC Laboratory of Molecular Biology
Janet Kumita, Pharmacology
Heike Laman, Pathology
Catherine Lindon, Pharmacology
Laura Machesky, Biochemistry
Frank McCaughan, Victor Phillip Dahdaleh Heart & Lung Research Institute
Ioanna Mela, Pharmacology
Eric Miska, Biochemistry
Julian Willis, Chemistry
Catherine Wilson, Pharmacology
Work with us
Collaboration is at the heart of the success of the University of Cambridge, enabling us to make discoveries that change the world.
Our pioneering work in nanomedicine, drug delivery, and precision medicine is driving breakthrough discoveries for the future of therapeutics.
We welcome opportunities to collaborate with colleagues from academia and industry, policy makers, lived experience partners and philanthropists.
To explore opportunities to work together, please contact:
Dr Abi Herrmann, Research Strategy Manager
School of the Biological SciencesAbi.Herrmanndmin.cam.ac.uk
To learn more about supporting this vital research, please contact:
Holly Singlehurst, Associate Director, Biological Sciences
Cambridge University Development and Alumni Relations Office
Holly.Singlehurst@admin.cam.ac.uk